{'fraction_non_alphanumeric': 0.03853211009174312, 'fraction_numerical': 0.025688073394495414, 'mean_word_length': 5.348837209302325, 'pattern_counts': {'":': 0, '<': 2, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Dolutegravir monotherapy and weight gain in naive patients with <100,000 copies/ml HIV RNA:an extended follow-up.

We previously reported our experience in 20 HIV-infected patients, naïve to HAART and with a zenith HIV RNA<100,000 copies/ml, followed at the Infectious Diseases Outpatient Department of G.B. Rossi Hospital in Verona, Italy, who started dolutegravir (DGT) monotherapy after refusing nucleoside reverse transcriptase inhibitors. We now report the results of an extended follow-up of the patients still on dolutegravir monotherapy.